Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Isabella Visuri"'
Autor:
Isabella Visuri, Carl Eriksson, Sara Karlqvist, Byron Lykiardopoulos, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almer, Erik Hertervig, Jan Marsal, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjöberg, Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Real-world data on long-term outcomes of vedolizumab (VDZ) are scarce. Objective: To assess long-term outcomes (up to 3 years) of VDZ in treating inflammatory bowel disease (IBD). Design: A nationwide, prospective multicentre extension of
Externí odkaz:
https://doaj.org/article/520ccc3a7100409a8d39655c69ab7181
Autor:
Ola Olén, Isabella Visuri, Pär Myrelid, Anders Gustavsson, Yang Cao, Carl Eriksson, Pontus Karling, Jonas F. Ludvigsson, Jonas Halfvarson, Olof Grip, Henrik Hjortswang, Emelie Mårdberg, Scott Montgomery
Publikováno v:
Alimentary Pharmacology & Therapeutics. 54:931-943
Background: Whether long-term effectiveness differs between anti-tumour necrosis factor (anti-TNF) agents is unknown. Aims: To examine drug survival of first-line anti-TNF agents and identify predictors of discontinuation. To reduce channelling bias,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06c1bbfd61429dc93042699116205b7
https://doi.org/10.1111/apt.16525
https://doi.org/10.1111/apt.16525
Autor:
Erik Hertervig, Lina Vigren, Carl Eriksson, Sven Almer, Linda Nilsson, Henrik Hjortswang, Anders Kärnell, Per Karlén, Daniel Bergemalm, Isabella Visuri, Jonas Halfvarson, Hans Strid
Objectives Clinical trials demonstrated that golimumab is effective in anti-TNF naive patients with ulcerative colitis. We aimed to assess the clinical effectiveness of golimumab in a real-world setting. Materials and methods This was a prospective c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2dc8112d00c957deee56b63c8266a97
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-178750
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-178750
Autor:
Yang Cao, Scott Montgomery, Anders Gustavsson, Olof Grip, Isabella Visuri, Pär Myrelid, Ola Olén, Henrik Hjortswang, Carl Eriksson, Emelie Mårdberg, Pontus Karling, Jonas Halfvarson, Jonas F. Ludvigsson
Publikováno v:
Alimentary Pharmacology & Therapeutics. 54:848-849
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4ed33eab168fdf71a286af67214fa50
https://doi.org/10.1111/apt.16569
https://doi.org/10.1111/apt.16569
Autor:
Ida Schoultz, Malin Olsson, Jonas Bengtsson, Michael Eberhardson, Marie Andersson, Isabella Visuri, Jan Björk, Martin Rejler, Michael C. Sachs, Scott Montgomery, Susanna Jäghult, Mattias Block, Carl Eriksson, Hans Strid, Anders Gustavsson, Olof Grip, Henrik Hjortswang, Eva Angenete, Åsa H Everhov, Ulrika L. Fagerberg, Sarita Shrestha, Pontus Karling, Jonas Halfvarson, Jonas F. Ludvigsson, Ola Olén, Per M. Hellström, Caroline Nordenvall, Pär Myrelid
Publikováno v:
Scandinavian journal of gastroenterology. 55(4)
Introduction: Whether data on International Classification of Diseases (ICD)-codes from the Swedish National Patient Register (NPR) correctly correspond to subtypes of inflammatory bowel disease (IBD) and phenotypes of the Montreal classification sch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d341b58b6875bc6298eb706450a4215
https://pubmed.ncbi.nlm.nih.gov/32370571
https://pubmed.ncbi.nlm.nih.gov/32370571
Autor:
Pontus Karling, Anders Gustavsson, Jonas Halfvarson, Isabella Visuri, Pär Myrelid, Henrik Hjortswang, Scott Montgomery, Ola Olén, Emelie Mårdberg, Olof Grip, Jonas F. Ludvigsson, Carl Eriksson
Publikováno v:
Journal of Crohn's and Colitis. 13:S443-S444
Background: Studies comparing drug survival in different anti-tumour necrosis factor (TNF) agents in IBD patients are scarce, especially for second-line anti-TNF agents. We aimed to (A) assess drug ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78886446bcc3addf8c29016f0e3994ad
https://doi.org/10.1093/ecco-jcc/jjy222.773
https://doi.org/10.1093/ecco-jcc/jjy222.773
Autor:
Lina Vigren, Henrik Hjortswang, Carl Eriksson, Isabella Visuri, Daniel Bergemalm, Hans Strid, M. Seddighzadeh, Erik Hertervig, Per Karlén, Ruzan Udumyan, Linda Nilsson, Sven Almer, Jonas Halfvarson
Publikováno v:
Journal of Crohn's and Colitis. 12:S409-S410
Clinical effectiveness of golimumab : Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f436ee9019747ab7cfbb18fe0146d12
https://doi.org/10.1093/ecco-jcc/jjx180.722
https://doi.org/10.1093/ecco-jcc/jjx180.722